Fomc-cis-L-hydroxyproline-OH
Product Code：B201360
English Name：Fomc-cis-L-hydroxyproline-OH
English Alias：(2S,4S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-4-hydroxypyrrolidine-2-carboxylic acid
CAS No.：189249-10-3
Molecular Formula：C₂₀H₁₉NO₅
Molecular Weight：353.37
High Purity：Confirmed by HPLC (≥99.0%), NMR (1H, 13C), HRMS, and elemental analysis, suitable for precise modification of cis-hydroxyproline derivatives in peptide synthesis.
Excellent Stability：Stable for 36 months at -20℃ under light-protected, sealed storage; well-soluble in common organic solvents (e.g., DMF, DCM) with degradation rate <0.5% within 6 months, ensuring synthesis reliability.
Peptide Drug Synthesis：As an Fmoc-protected cis-hydroxyproline monomer, used in solid-phase peptide synthesis (SPPS) to construct functional peptides containing hydroxyproline, such as antifibrotic peptides and enzyme inhibitors.
Drug Development Tool：Modulates peptide conformational stability and biological activity by introducing hydroxyproline structure in new drug development, e.g., improving serum stability or target binding capacity.
Biochemical Research：Used to study protein-protein interactions or as a probe molecule to label biomacromolecules, regulating molecular recognition properties via hydroxyl hydrophilicity.
Hydroxyproline, an important non-natural amino acid, widely exists in natural products like collagen, and its cis configuration is crucial for maintaining protein secondary structure. Fomc-cis-L-hydroxyproline-OH, as an Fmoc-protected cis-isomer, protects the amino group with fluorenylmethoxycarbonyl (Fmoc) to avoid racemization during synthesis while retaining the reactivity of the 4-hydroxy group. This compound enhances peptide structural rigidity in peptide drug design, often used to develop therapeutic peptides with specific spatial conformations, such as anti-tumor and anti-inflammatory drugs.
Synthesis Process：Prepared by condensation of fluorenylmethoxycarbonyl chloride with cis-L-hydroxyproline under alkaline conditions (e.g., NaHCO₃/DCM system), with optimized reaction temperature (0-5℃) and purification (reverse-phase preparative HPLC), yielding over 75%.
Application Progress：Recent studies show that peptides containing this monomer exhibit excellent activity in treating fibrotic diseases, such as reducing collagen deposition by inhibiting TGF-β signaling; additionally, used as a linker component in ADC drugs to modify antibodies or toxin molecules via hydroxyl groups, improving conjugate stability.
Analytical Techniques：Circular dichroism (CD) and X-ray crystallography verify β-turn structures induced in peptides, while UPLC-MS/MS monitors impurities (e.g., trans-isomers, deprotected products) during synthesis to ensure product uniformity.
WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com
NOTE！
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com
NEW IN STOCK!
The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!
China
